Denosumab Fracture Intervention Randomized Placebo Controlled Trial in Japanese Patients With Osteoporosis
Launched by DAIICHI SANKYO CO., LTD. · May 19, 2008
Trial Information
Current as of April 25, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Involutional (postmenopausal and senile) osteoporosis with prevalent fragility vertebral fractures
- Exclusion Criteria:
- • Any underlying condition,(other than BMD) that might have resulted in abnormal bone metabolism
Trial Officials
Daiichi Sankyo
Study Chair
R&D Division, Daiichi Sankyo Co., Ltd.
About Daiichi Sankyo Co., Ltd.
Daiichi Sankyo Co., Ltd. is a global healthcare company headquartered in Tokyo, Japan, renowned for its commitment to innovative research and development in pharmaceuticals. With a rich history spanning over a century, the company focuses on delivering transformative treatments across various therapeutic areas, including oncology, cardiovascular disease, and infectious diseases. Daiichi Sankyo leverages cutting-edge science and technology to advance its drug development pipeline, emphasizing collaboration and partnership to enhance patient outcomes worldwide. Its dedication to improving global health is reflected in its extensive clinical trials, which aim to bring novel therapies to market and address unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tokyo, , Japan
Fukuoka, , Japan
Osaka, , Japan
Sapporo, , Japan
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials
Related Blog Entries
View all
